Is Zhejiang Hisun Pharmaceutical (SHSE:600267) Using Too Much Debt?

Simply Wall StDec 19 20:02 ET

Zhejiang Hisun Pharmaceutical (600267.SH): Apremilast tablets and posaconazole enteric-coated tablets are expected to win centralized procurement bidding.

Zhejiang Hisun Pharmaceutical (600267.SH) announced that on December 12, 2024, the company participated in a joint procurement...

Zhitong FinanceDec 13 06:08 ET

Zhejiang Hisun Pharmaceutical (600267.SH): Participation in the national pharmaceutical centralized procurement aims to win the bid.

Gelonghui reported on December 13 that Zhejiang Hisun Pharmaceutical (600267.SH) announced that on December 12, 2024, the company participated in the bidding for the 10th batch of national centralized pharmaceutical procurement organized by the Joint Procurement Office (hereinafter referred to as the "Joint Procurement Office"). After the opening and evaluation of bids by the Joint Procurement Office, the company's products, Aprepitant tablets and Posaconazole enteric-coated tablets, are proposed to win the bid for this centralized procurement. Aprepitant tablets and Posaconazole enteric-coated tablets have been selected for supply provinces based on the market potential of each province, and the results of the selection will be officially announced after being posted by the Joint Procurement Office.

Gelonghui FinanceDec 13 05:42 ET

Zhejiang Hisun Pharmaceutical (600267.SH): Meropenem is currently still in the first round of centralized procurement period, with small sales volume

Gelonghui reported on November 15 that zhejiang hisun pharmaceutical (600267.SH) stated on the interactive platform that meropenem is currently still in the first round of centralized procurement period, and the sales volume is not large. The company will closely monitor subsequent procurement opportunities; the company has many products and is recovering well through diversified operation. The entire company is striving to reach the performance targets set at the beginning of the year, with the industrial team continuously improving process levels. The cost reduction and efficiency enhancement work has shown initial results this year, and substantial progress in industrial capacity recovery is expected to begin next year.

Gelonghui FinanceNov 15 03:16 ET

China Approves Hisun Pharma's Two Medications for Dogs

MT NewswiresNov 15 03:00 ET

Benign Growth For Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) Underpins Its Share Price

Simply Wall StNov 8 18:02 ET